Correction to: Higher Expression of Caveolin-1 Inhibits Human Small Cell Lung Cancer (SCLC) Apoptosis In Vitro (Cancer Investigation, (2012), 30, 6, (453-462), 10.3109/07357907.2012.675384);Higher expression of caveolin-1 inhibits human small cell lung cancer (SCLC) apoptosis in vitro

Cancer Investigation

Volumn 30, Issue 6, 2012, Pages 453-462

  Yang, Xiaohan ^a   Xiong, Hai ^a   Guan, Zhu Zhu ^a   Okai, Isaac ^a   Ye, Dongmei ^a,b   Song, Yang ^a   Li, Xiao ^c   Wang, Lan ^a   Liu, Lu ^a   Du, Sha ^a   Lin, Dongmei ^d   Shao, Shujuan ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b DALIAN UNIVERSITY   (China)

^c DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^d PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Caveolin 1; Small cell lung cancer

Indexed keywords

CASPASE 3; CAVEOLIN 1; CISPLATIN; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ULTRAVIOLET RADIATION;

EID: 84861725952     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357907.2020.1750155     Document Type: Erratum

References (42)

1. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell 2002;1:49-52. (Pubitemid 41039175)
2. Fischer B, Arcaro A. Current status of clinical trials for small cell lung cancer. Rev Recent Clin Trials 2008;3:40-61. (Pubitemid 351267025)
3. Page NC, Read WL, Tierney RM, Arquette MA, Piccirillo JF, Govindan R. The epidemiology of small cell lung carcinoma. Proc Am Soc Clin Oncol 2002;21:305A (abstract 1216).
4. Ferraldeschi R, Baka S, Jyoti B, Faivre-Finn C, Thatcher N, Lorigan P. Modern management of small-cell lung cancer. Drugs 2007;67:2135-2152. (Pubitemid 47557091)
5. James LE, Rudd RM, Gower NH, Gregory W, Lee SM, Eisen T, Ellis P, Gilligan D, Ferry D, Spiro SG. A phase III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2002;21:1170-1175.
6. Lutzker SG, Levine AJ. Apoptosis and cancer chemotherapy. Cancer Treat Res 1996;87:345-356.
7. Forero-Torres A, Shah J,Wood T, Posey J, Carlisle R, Copigneaux C, Luo FR, Wojtowicz-Praga S, Percent I, Saleh M. Phase I trial of weekly tigatuzμMab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 2010;25:13-19.
8. Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Nature Immunol 2003;4:410-415. (Pubitemid 36592430)
9. Kato T, Miyamoto M, Kato K, Cho Y, Itoh T, Morikawa T, Okushiba S,Kondo S,Ohbuchi T,KatohH.Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma. Cancer Lett 2004;214:121-128. (Pubitemid 39141205)
10. Rejman J, ConeseM, Hoekstra D. Gene transfer bymeans of lipoand polyplexes: role of clathrin and caveolae-mediated endocytosis. J Liposome Res 2006;16:237-247. (Pubitemid 44358997)
11. Razani B, Schlegel A, Liu J, LisantiMP. Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans 2001;29:494-499. (Pubitemid 32783645)
12. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation cancer, and metastasis. Am J Physiol Cell Physiol 2005;288:C494-C506. (Pubitemid 40229478)
13. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998;4:1873-1880. (Pubitemid 28369170)
14. Yang G, Truong LD,Wheeler TM,Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker. Cancer Res 1999;59:5719-5723.
15. Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK. Caveolin-1 expression is associated with high-grade bladder cancer. Urology 2001;58:811-814.
16. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002;94:929-933. (Pubitemid 34150846)
17. Sunaga N, Miyajima K, Suzuki M, Sato M. White MA, Ramirez RD, Shay JW, Gazdar AF, Minna JD. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 2004;64:4277-4285. (Pubitemid 38802434)
18. Kerr JF,Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
19. SamsonDJ, Seidenfeld J, Simon GR, TurrisiAT, Bonnell C, Ziegler KM, Aronson N. Evidence formanagement of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;32:314S-423S.
20. Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D. Randomized study of CODE versus alternating CAV/EP for extensivestage small-cell lung cancer: An intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:2300-2308. (Pubitemid 29368227)
21. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801. (Pubitemid 29269249)
22. Elke B, Mordechai L, Christoph R, Roland MS, Matthias PAE. Caveats of caveolin-1 in cancer progression. Cancer Lett 2008;268:187-201.
23. Lockhart C, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 2005;32(1):52-60. (Pubitemid 40250126)
24. Anderson RG. The Caveolae membrane system. J Annu Rev Biochem 1998;67:199-225. (Pubitemid 28411129)
25. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Cancer Inst 1990;82(9):749-755. (Pubitemid 20159274)
26. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279. (Pubitemid 37487159)
27. Wolbers F, Buijtenhuijs P, Haanen C, Vermes I. Apoptotic cell death kinetics in vitro depend on the cell types and the inducers used. Apoptosis 2004;9:385-392. (Pubitemid 38981513)
28. Stennicke HR, Ryan CA, Salvesen GS. Reprieval from execution: The molecular basis of caspase inhibition. Trends Biochem Sci 2002;27:94-101. (Pubitemid 34164325)
29. Wolf BB, Schuler M, Echeverri F, Green DR. Caspase-3 is the primary activator apoptotic DNA fragmentation factor-45/inhibitor of caspase- activated DNase in activation. J Biol Chem 1999;274(43):30651-30656.
30. Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ. Posttranslational N-myristoy-lation of Bid as a molecular switch for targeting mitochondria and apoptosis. Science 2000;290(5497):1761-1765. (Pubitemid 32004806)
31. Boehning D, Patterson RL, Sedaghat L, Glebova NO, Kurosaki T, Snyder SH. Cytochrome c binds to inositol (1, 4, and 5) trisphosphate receptors, amplifying caldum-dependent apoptosis. Nat Cell Biol 2003;5:1051-1061. (Pubitemid 37509111)
32. Boehning D, van RossumDB, Patterson RL, Snyder SH. A peptide inhibitor of cytochrome c/inositol 1, 4, 5-Trisphosphate receptor binding blocks intrinsic and extrinsic cell death pathways. Proc Nati Acad Sci US 2005;102:1466-1471. (Pubitemid 40209193)
33. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial mitochondrial membrane. Mol Cell Biol 2000;20:929-935. (Pubitemid 30044230)
34. Harris MH, Thompson CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 2000;7(12):1182-1191. (Pubitemid 32042225)
35. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapyinduced apoptosis in a human leukemia cell line. Blood 1993;81(1):151-157. (Pubitemid 23013689)
36. IkegakiN, Katsumata M,Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994;54:6-8. (Pubitemid 24042076)
37. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994;145:1036-1040. (Pubitemid 24345651)
38. Santos AO, Pereira JP, Pedroso De Lima MC, Simoes S, Moreira JN. In vitro modulation of Bcl-2 levels in small cell lung cancer cells: Effects on cell viability. Braz J Med Biol Res 2010;43(10):1001-1009.
39. Zhao X, Liu Y, Ma Q, Wang X, Jin H, Mehrpour M, Chen Q. Caveolin-1 negatively regulates TRAIL-induced apoptosis in human hepatocarcinoma cells. Biochem Biophys Res Commun 2009;378(1):21-26.
40. Wu P, Qi B, Zhu H, Zheng Y, Li F. Suppression of stauro sporinemediated apoptosis in Hs578T breast cells through inhibition of neutral- sphingomyelinase by caveolin-1. Cancer 2007;256:64-72. (Pubitemid 47333326)
41. Zhang Z, Yao K, Jin C. Apoptosis of lens epithelial cells induced by high concentration of glucose is associated with a decrease in caveolin-1 levels. Molecular Vision 2009;15:2008-2017.
42. Li L, Ren, CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003;23:9389-9404. (Pubitemid 37499824)